A 62-year-old with HFrEF (EF 30%) on metoprolol succinate and furosemide remains symptomatic (NYHA II). Which addition provides mortality benefit per ...

Question

A 62-year-old with HFrEF (EF 30%) on metoprolol succinate and furosemide remains symptomatic (NYHA II). Which addition provides mortality benefit per guideline-directed therapy?

Accepted Answer

Sacubitril/valsartan

Answer

Diltiazem

Answer

Ivabradine as monotherapy

Answer

Pioglitazone

Answer

Verapamil

us-abim MCQ (SBA): Heart Failure (HFrEF)

A 62-year-old with HFrEF (EF 30%) on metoprolol succinate and furosemide remains symptomatic (NYHA II). Which addition provides mortality benefit per guideline-directed therapy?